Editorial Comment

Purpose: For patients with bacillus Calmette-Guerin unresponsive or recurrent/relapsing nonmuscle invasive bladder cancer, multi-agent intravesical trialshave been limited. In this study we investigate the safety of intravesical cabazitaxel, gemcitabine and cisplatin in the salvage setting. Materials and Methods: This was a dose escalation, drug escalation trial for patients with bacillus Calmette-Guerin unresponsive or recurrent/relapsing nonmuscle invasive bladder cancer who declined or were ineligible for radical cystectomy. All patients underwent a 6-week induction regimen of sequentially administered cabazitaxel, gemcitabine and cisplatin. Complete response was defined as no cancer on post-induction transurethral bladder tumor resection and negative urine cytology, while partial response allowed for positive cytology. Responders continued with maintenance cabazitaxel and gemcitabine monthly for the first year and bimonthly for the second year. Results: A total of 18 patients were ...